Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

Blood (2023) 142 (Supplement 1): 6935.

https://doi.org/10.1182/blood-2023-189047

Published: 2023

Journal Articles

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Blood (2023) 142 (Supplement 1): 4190.

https://doi.org/10.1182/blood-2023-185875

Published: 2023

Journal Articles

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Ann-Kristin Schmälter, Maud Ngoya, Jürgen Finke, Nicolaus Kröger, Friedrich Stölzel, Matthias Stelljes, Thomas Valerius, Johanna Tischer, Thomas Schroeder, Peter Dreger, Igor Wolfgang Blau, Bipin Savani, Sebastian Giebel, Jordi Esteve, Ali Bazarbachi, Arnon Nagler, Christoph Schmid, Fabio Ciceri, Mohamad Mohty

Blood (2022) 140 (Supplement 1): 4799–4801.

https://doi.org/10.1182/blood-2022-163788

Published: 2022

Journal Articles

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Blood (2022) 140 (Supplement 1): 2110–2112.

https://doi.org/10.1182/blood-2022-162277

Published: 2022

Journal Articles

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Blood (2022) 140 (1): 45–57.

https://doi.org/10.1182/blood.2021014485

Published: 2022

Includes: Supplemental data

Journal Articles

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Blood (2021) 138 (Supplement 1): 3903.

https://doi.org/10.1182/blood-2021-144748

Published: 2021

Journal Articles

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Blood (2021) 138 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2021-152208

Published: 2021

Journal Articles

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Lennart Lenk, Dorothee Winterberg, Fotini Vogiatzi, Anna Laqua, Lea Spory, Ahmad Mayar, Christian Vokuhl, Julia Richter, Michela Carlet, Irmela Jeremias, Thomas Valerius, Martin Schrappe, Gunnar Cario, Hassan Jumaa, Elias Hobeika, Monika Brüggemann, Ameera Alsadeq, Denis Martin Schewe

Blood (2021) 138 (Supplement 1): 2388.

https://doi.org/10.1182/blood-2021-148429

Published: 2021

Journal Articles

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Fotini Vogiatzi, PhD, Kristina Müller, Dorothee Winterberg, Thies Rösner, PhD, Lennart Lenk, PhD, Gunnar Cario, MD PhD, Martin Schrappe, MDPhD, Andreas E. Kulozik, MD PhD, Beat Bornhauser, Jean-Pierre Bourquin, MD PhD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-140270

Published: 2020

Journal Articles

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Judith Petersen, Thies Rösner, PhD, Max Kölling, Katja Klausz, PhD, Christian Kellner, PhD, Andreas Humpe, MD, George J Weiner, MD, Denis Martin Schewe, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2019) 134 (Supplement_1): 5305.

https://doi.org/10.1182/blood-2019-122940

Published: 2019

Journal Articles

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Fotini Vogiatzi, Dorothee Winterberg, Lennart Lenk, Swantje Buchmann, Gunnar Cario, Martin Schrappe, Matthias Peipp, Paulina Richter-Pechanska, Andreas E. Kulozik, Jana Lentes, Anke K. Bergmann, Thomas Valerius, Fabian-Simon Frielitz, Christian Kellner, Denis M. Schewe

Blood (2019) 134 (8): 713–716.

https://doi.org/10.1182/blood.2019000904

Published: 2019

Includes: Supplemental data

Journal Articles

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Thorsten Ross, PhD, Uwe Reusch, PhD, Susanne Wingert, PhD, Torsten Haneke, PhD, Katja Klausz, PhD, Anna-Kathrin Otte, PhD, Natalie Schub, MD, Stefan Knackmuss, PhD, Thomas Müller, Kristina Ellwanger, PhD, Ivica Fucek, Ute Schniegler-Mattox, Joachim Koch, PhD, Thomas Valerius, MD, Martin Gramatzki, MD, Matthias Peipp, PhD, Michael Tesar, PhD, Erich Rajkovic, PhD MBA, Martin Treder, PhD

Blood (2018) 132 (Supplement 1): 1927.

https://doi.org/10.1182/blood-2018-99-118970

Published: 2018

Journal Articles

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

Fotini Vogiatzi, PhD, Julia Heymann, Thies Rösner, PhD, Lennart Lenk, PhD MSc, Gunnar Cario, MD, Martin Schrappe, MD PhD, Beat Bornhauser, PhD, Jean-Pierre Bourquin, MD PhD, Simon Bomken, MD, Thomas Valerius, MD, Matthias Peipp, PhD, Christian Kellner, PhD, Denis Martin Schewe, MD

Blood (2018) 132 (Supplement 1): 4177.

https://doi.org/10.1182/blood-2018-99-114677

Published: 2018

Journal Articles

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL -rearranged acute lymphoblastic leukemia xenografts

Denis M. Schewe, Ameera Alsadeq, Cornelia Sattler, Lennart Lenk, Fotini Vogiatzi, Gunnar Cario, Simon Vieth, Thomas Valerius, Sophia Rosskopf, Fabian Meyersieck, Julia Alten, Martin Schrappe, Martin Gramatzki, Matthias Peipp, Christian Kellner

Blood (2017) 130 (13): 1543–1552.

https://doi.org/10.1182/blood-2017-01-764316

Published: 2017

Includes: Supplemental data

Journal Articles

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Denis M Schewe, MD, Ameera Alsadeq, PhD, Gunnar Cario, MD, Simon Vieth, MD, Thomas Valerius, MD, Martin Schrappe, MD PhD, Martin Gramatzki, MD, Matthias Peipp, PhD, Christian Kellner, PhD

Blood (2016) 128 (22): 277.

https://doi.org/10.1182/blood.V128.22.277.277

Published: 2016

Journal Articles

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Anna Kretschmer, Stefan Lohse, PhD, Thies Rösner, PhD, Marco J.H. Jansen, Christian Kellner, PhD, Matthias Peipp, PhD, Mark S Cragg, PhD, Ameera Alsadeq, PhD, Denis M Schewe, MD, Jeanette H.W. Leusen, PhD, Thomas Valerius, MD

Blood (2016) 128 (22): 1835.

https://doi.org/10.1182/blood.V128.22.1835.1835

Published: 2016

Journal Articles

Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia

Henning Fedders, PhD, Ameera Alsadeq, PhD, Britt-Sabina Petersen, PhD, Christian Kellner, PhD, Matthias Peipp, PhD, Thomas Valerius, MD, Robert Haesler, PhD, Julia Alten, MD, Anja Möricke, Susanne Strube, PhD, Thomas Wiesel, MD, Gunnar Cario, MD, Martin Schrappe, Andre Franke, PhD, Martin Stanulla, MD, Denis Martin Schewe, MD

Blood (2014) 124 (21): 3791.

https://doi.org/10.1182/blood.V124.21.3791.3791

Published: 2014

Journal Articles

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Matthias Peipp, PhD, Christian Kellner, PhD, Andreas Günther, MD, Andreas Humpe, MD, Roland Repp, MD, Katja Klausz, PhD, Stefanie Derer, PhD, Thomas Valerius, MD, Jan G.J. van de Winkel, PhD, Paul W.H.I. Parren, PhD, Martin Gramatzki, MD

Blood (2014) 124 (21): 1779.

https://doi.org/10.1182/blood.V124.21.1779.1779

Published: 2014

Journal Articles

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Stefanie Derer, PhD, Thies Rösner, Stefan Lohse, PhD, Matthias Peipp, PhD, Thomas Valerius, MD

Blood (2014) 124 (21): 3506.

https://doi.org/10.1182/blood.V124.21.3506.3506

Published: 2014

Journal Articles

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Stefanie Derer, PhD, Pia Glorius, PhD, Martin Schlaeth, Stefan Lohse, PhD, Umesh Muchhal, Ph.D., John Desjarlais, Andreas Humpe, MD, Thomas Valerius, MD, Matthias Peipp, PhD

Blood (2013) 122 (21): 3466.

https://doi.org/10.1182/blood.V122.21.3466.3466

Published: 2013

NARROW

Pseudoprogression As Adverse Event of Chimeric Antigen Receptor T Cell Therapy

A Novel Fc-Optimized Antibody Drug Conjugate Targeting CD7 As a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia

Continuously Improving Outcome over Time after Second Allogeneic Stem Cell Transplantation in Relapsed Acute Myeloid Leukemia - a Retrospective Analysis of 1540 Patients on Behalf of the Acute Leukemia Working Party of EBMT

Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation - a Registry Study on Behalf of the EBMT Acute Leukemia Working Party

Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL

Donor Genetic Determinant of Thymopoiesis rs2204985 Impacts Clinical Outcome after Single HLA Mismatched HSCT

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Preclinical Evidence for the Efficacy of CD79b Immunotherapy in B Cell Precursor Acute Lymphoblastic Leukemia

Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia

Blockade of CD47-Sirpα Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab

Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia

Preclinical Characterization of AFM26, a Novel B Cell Maturation Antigen (BCMA)-Directed Tetravalent Bispecific Antibody for High Affinity Retargeting of NK Cells Against Myeloma

Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies

An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL -rearranged acute lymphoblastic leukemia xenografts

An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells

Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunoescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia

Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30

Switching from IgG1 to IgG3 Isotype to Boost Complement-Activating Capacities of Therapeutic Antibodies – Impact of CD55 Expression on the Mode of Action

Ratios Of FcγRIIa and FcγRIII Binding Affinities Govern The Efficacy Of PMN-Mediated Cytotoxicity – Implications For Fc-Engineering Approaches Of Therapeutic Antibodies

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only